Article
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.
Lancet (London, England) - 8 Feb 2014
Lawitz Eric, Poordad Fred F, Pang Phillip S, Hyland Robert H, Ding Xiao, Mo Hongmei, Symonds William T, McHutchison John G, Membreno Fernando E
Abstract excerpt
BACKGROUND: Interferon-based treatment is not suitable for many patients with hepatitis C virus (HCV) infection because of contraindications such as psychiatric illness, and a high burden of adverse events. We assessed the efficacy and safety of an interferon-free regimen--a fixed-dose combination of the nucleotide polymerase inhibitor sofosbuvir (400 mg) and the HCV NS5A inhibitor ledipasvir (90 mg), with and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.